2010 First-Half Review

06 September, 2010

The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, September 3, 2010 to approve the Group’s consolidated financial statements for the six months ended June 30, 2010. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors, who had performed a limited review of the financial statements.

Continued Profitability Growth

  • Operating income before non-recurring items up 10.8%
  • Net income up 13.7%

Two acquisitions in China and five new partnership agreements
A solid R&D pipeline
An ambitious industrial plan

 

Pioneering Diagnostics